We are live on ! Find out more
OGEN icon

Oragenics
OGEN

11 hedge funds and large institutions have $2.29M invested in Oragenics in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 11 → 11 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

0.01% less ownership

Funds ownership: 0.02% → 0.01% (-0.01%)

16% less capital invested

Capital invested by funds: $2.73M → $2.29M (-$438K)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
11
Holders Change
–
Holders Change %
0%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WC
Wexford Capital
Florida
+$384K
2
Barclays
Barclays
United Kingdom
+$34.6K
3
TSS
Two Sigma Securities
New York
+$32.3K
4
Citadel Advisors
Citadel Advisors
Florida
+$19.6K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$107K
2
VF
Virtu Financial
New York
-$16.1K
3
UBS Group
UBS Group
Switzerland
-$7K
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.92K
5
Deutsche Bank
Deutsche Bank
Germany
-$2K

OGEN Hedge Fund Activity: Q3 2018 in Review

11 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Oragenics (OGEN) for Q3 2018, worth a combined $2.29M — down 16% from $2.73M a quarter earlier.

Fund positioning in OGEN was balanced in Q3 2018: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 2 trimmed.

The largest buyer was Wexford Capital, opening a new position worth an estimated $384K. The largest seller was Morgan Stanley, exiting entirely with an estimated $107K sold.

  • 11 institutional investors held Oragenics (OGEN) as of Q3 2018, unchanged from Q2 2018.
  • Funds reported $2.29M of Oragenics stock for Q3 2018, down 16% quarter-over-quarter.
  • 3 funds opened new Oragenics positions in Q3 2018 and 3 closed out, a net change of 0 holders.
  • The largest Oragenics buyer in Q3 2018 was Wexford Capital, an estimated $384K added.
  • The largest Oragenics seller in Q3 2018 was Morgan Stanley, an estimated $107K sold.

Based on aggregated 13F filings for Q3 2018.